Weight-Loss drug tirzepatide takes on heart flutter in new trial

NCT ID NCT06802081

Recruiting now Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study at the Cleveland Clinic will test whether the weight-loss drug tirzepatide (Zepbound) can help people with obesity and atrial fibrillation (AFib). About 100 participants will receive weekly injections of tirzepatide or a placebo for up to 12 months. The main goal is to see if weight loss reduces the total time spent in AFib and improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirzepatide (Zepbound)
What this could lead to: If successful, this could show that weight loss with tirzepatide helps control atrial fibrillation symptoms and reduce time spent in AFib.
What could go wrong: This is a small, early-phase trial (100 people) at one center. Results may not apply to everyone, and tirzepatide has side effects like nausea and vomiting. The study is not designed to prove long-term safety or efficacy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION OBESITY

Contacts and locations

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.